Despite its relatively low profile since it kicked off its third phase last spring, the Broad Institute's RNAi Consortium is proceeding apace, although its mission has expanded beyond its initial focus of just RNAi.
This article originally ran on May 15 and has been updated to include additional comments from GlaxoSmithKline.
GlaxoSmithKline said today that it has entered an agreement to purchase chemical proteomics firm Cellzome for £61 million ($99 million).
By Adam Bonislawski
University of North Carolina researchers have developed a chemical proteomics approach to measure global kinase activity and used it to investigate drug resistance in triple-negative breast cancer.
Belgian protein biomarker firm Pronota has raised €3.7 million ($4.9 million) a Series C financing round that it will use to complete protein biomarker validation studies for its pre-eclampsia, ovarian cancer, sepsis, and cardio-renal programs.
Foundation Medicine has struck a deal with Johnson & Johnson Pharmaceutical Research and Development to use Foundation's targeted sequencing cancer test to identify potential biomarkers that could be of interest for the pharmaceutical company's clinical oncology programs.
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Foundation Medicine today said that it will partner with Johnson & Johnson Pharmaceutical Research and Development in a biomarker identification collaboration.